Move your pipeline forward, with confidence.
Simmunome generates in silico disease models that accurately capture physiological processes to predict the probability of success of your drug.
Accurate.
Built upon robust, peer-reviewed public datasets, our models have a high level of accuracy from the outset. Simulations of physiological events are further supported by real world evidence from existing clinical trials.
Comprehensive.
We combine fragmented data to create holistic models of diseases that tranlsate into helping you understand your drug’s mechanism of action, increase efficacy in the right target population and predict your drug’s safety profile.
Explainable.
Causality, not correlation. Unlike traditional statistical methods and blackbox AI approaches, our machine learning algorithms utilize multi-omic data structures to create causal representations of the biological events leading to disease onset.
THE SIMMUNOME ADVANTAGE
Know the Probability of Success in Seconds.
Leveraging generative AI to untangle biological complexity.
Biology is complex. We create in multi-omic disease models that accurately capture physiological processes to enhance the predictability of clinical drug development.
Therapeutic Areas of Focus
-
Breast Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Melanoma
-
Alzheimer’s Disease
Parkinson’s Disease
ALS
-
Tissue Repair
Don’t see your therapeutic area here? Simmunome can develop disease models for your specific indication. 
Use Cases.
We de-risk clinical development in seconds. See what we’re talking about with our real world examples.
-
Epidermal growth factor (EGFR) is a protein target of many drugs for cancer. Predicted efficacy for EGFR as a target for breast cancer was predicted by our model to be 42.9%. Efficacy in clinical trials has shown to be between 24 and 56%.
-
β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) was tested as a protein target for Alzheimer’s Disease. Predicted efficacy for BACE1 as a target for Alzheimer’s. Disease was predicted by our model to be 0.0%.
Currently no drugs have been approved; several have been terminated for lack of efficacy.
Our Clients
-
Pharma
We help pharmas prioritize their assets, focus their efforts, and develop diagnostics.
-
Biotech
We help biotechs stretch their budgets and de-risk highly narrow portfolios and gain a competitive advantage.
-
Academia
We help academic researchers test biological hypotheses and bridge basic science with clinical research and medicine.
You Asked, We Answered
We put together this FAQ video to answer some of the most commonly asked questions about our technology.
🔍 Interested in learning about how AI can make drug development more efficient?
🧬 Curious about what type of clinical data is required?
🔬 Wondering when is the best time to integrate AI in your drug development process?
Simmunome believes in the responsible development of AI to benefit humanity.
Simmunome’s members are trained in the TRAIL program. The training program was initiated and designed under the supervision of Yoshua Bengio, Scientific Director at Mila. The program is aimed at teaching AI researchers to implement ethical, legal and governance considerations in their methodology and practices.